MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on February 22, 2007; DOI: 10.1124/mol.106.033449

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.033449v1
71/5/1427    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Riku Korhonen
Katrin Linker
Andrea Pautz
Ulrich Forstermann
Eeva Moilanen
Hartmut Kleinert
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Korhonen, R.
Right arrow Articles by Kleinert, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Korhonen, R.
Right arrow Articles by Kleinert, H.


Received for publication December 14, 2006.
Revised February 22, 2007.
Accepted for publication February 22, 2007.

Post-transcriptional regulation of human iNOS expression by the Jun N-terminal kinase

Riku Korhonen 1*, Katrin Linker 2, Andrea Pautz 2, Ulrich Forstermann 2, Eeva Moilanen 1, Hartmut Kleinert 2

1 University of Tampere 2 Johannes Gutenberg University

* Address correspondence to: E-mail: riku.korhonen{at}uta.fi

Abstract

Human inducible nitric oxide synthase (iNOS) expression is regulated both at transcriptional and post-transcriptional levels. In the present study, the effect of Jun N-terminal kinase (JNK) on human iNOS expression was investigated. In A549/8 human alveolar epithelial cells, both the inhibition of JNK by a pharmacological inhibitor SP600125 and siRNA-mediated down-regulation of JNK led to a reduction of iNOS mRNA and protein expression. iNOS promoter activity was not affected by these treatments. Hence, JNK seems to regulate iNOS expression through post-transcriptional mechanisms by stabilizing iNOS mRNA. Our laboratory has recently shown that a cytokine-induced RNA binding protein tristetraprolin (TTP) is a major positive regulator of human iNOS expression by stabilizing iNOS mRNA. Therefore, the effect of JNK inhibition by SP600125 or down-regulation by siRNA on TTP expression was investigated. Both SP600125 and siRNA targeted at JNK resulted in a reduction of TTP protein expression without affecting the amount of TTP mRNA. These data suggest a post-transcriptional control of TTP expression by JNK. Moreover, the modulation of JNK signaling by SP600125 or siRNA did not change p38 phosphorylation. In summary, the results suggest that JNK regulates human iNOS expression by stabilizing iNOS mRNA possibly by a TTP-dependent mechanism.


Key words: Nitric oxide synthases, MAP Kinase, Jun Kinase, Regulation - post-transcriptional


This article has been cited by other articles:


Home page
 Cancer Res.Home page
K. Engels, S. K. Knauer, S. Loibl, V. Fetz, P. Harter, A. Schweitzer, A. Fisseler-Eckhoff, F. Kommoss, L. Hanker, V. Nekljudova, et al.
NO Signaling Confers Cytoprotectivity through the Survivin Network in Ovarian Carcinomas
Cancer Res., July 1, 2008; 68(13): 5159 - 5166.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics